Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02691962 · ClinicalTrials.gov registry record · NA
Xen Matrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias
A NA study, sponsored by C. R. Bard.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
NCT02691962 is a NA study that has completed, run by C. R. Bard. The registered enrollment target is 75 participants.
The verdict
NCT02691962, a NA study, has completed, sponsored by C. R. Bard.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
Study Summary
This study aims to prospectively explore the use of XenMatrix™ AB Surgical Graft for ventral or incisional midline hernia repair in patients across all wound classes ("All Comers") through 24 months post repair.
Interventions
- DEVICE Xen Matrix AB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2016-05 |
| Est. Completion | 2020-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02691962
The ClinicalTrials.gov registry entry for NCT02691962 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xen Matrix AB is the first listed.
NCT02691962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02691962 about?
NCT02691962 is a clinical study titled "Xen Matrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias". This study aims to prospectively explore the use of XenMatrix™ AB Surgical Graft for ventral or incisional midline hernia repair in patients across all wound classes ("All Comers") through 24 months post repair.
What is the current status of trial NCT02691962?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2016-05. Estimated completion is 2020-05.
What interventions are being tested in trial NCT02691962?
The interventions under investigation include: Xen Matrix AB (DEVICE).
Who is sponsoring clinical trial NCT02691962?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.